“
TL;DR
It describes AD as a chronic inflammatory skin disease involving skin barrier disruption and immune dysregulation.
Pharmacological Reports · 3 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
It describes AD as a chronic inflammatory skin disease involving skin barrier disruption and immune dysregulation.
It describes AD as a chronic inflammatory skin disease involving skin barrier disruption and immune dysregulation. The authors note that nanoformulations can offer advantages like drug localization and reduced toxicity. However, they highlight significant safety concerns, including potential nanoparticle-induced immunological responses, cellular toxicity from reactive oxygen species, and the need for strict regulatory compliance. The conclusion emphasizes that while nanomedicine-based techniques are predicted to revolutionize dermatology, most existing studies lack clinical data, necessitating future research focused on clinical examination and establishing in vitro/in vivo correlations for regulatory translation.